Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + anlotinib
- Development stage
- Preclinical
- Lead developer
- RemeGen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Disitamab vedotin + anlotinib is a combination therapy being investigated for the treatment of various cancers, particularly HER2-expressing metastatic breast cancer. Disitamab vedotin (RC48) is a novel HER2-targeted antibody-drug conjugate that delivers the cytotoxic payload monomethyl auristatin E (MMAE) to HER2-expressing cancer cells. Anlotinib is a tyrosine kinase inhibitor. This combination is being studied to evaluate its efficacy and safety in patients with hormone receptor-negative, HER2-low-expressing metastatic breast cancer.
- Brand names
- Aidixi + Focus V
- Other names
- RC48 + anlotinib hydrochloridedisitamab vedotin and anlotinib hydrochloride combination
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFR3 (Vascular endothelial growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))FGFR (FGFR family)
Beyond the preview
Go deeper on disitamab vedotin + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + anlotinib.